Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
Scott Dryden‐Peterson(Harvard University), Ann E. Woolley(Evidence (Italy)), Rajesh T. Gandhi(Harvard University), Ellen C. Caniglia(Botswana Harvard AIDS Institute Partnership), Elizabeth Donahue(Brigham and Women's Hospital), Lindsay Gainer(Political Research Associates), Lisa Dutton(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Andy Kim(Brigham and Women's Hospital), Arthur Y. Kim(Harvard University), Rajesh Patel(Lahey Medical Center), Inga T. Lennes(Massachusetts General Hospital)
Cited by 42
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969